Symbols / FOLD Stock $14.46 +0.00% Amicus Therapeutics, Inc.
FOLD (Stock) Chart
About
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Stock Fundamentals
Scroll to Statements| Market Cap | 4.54B | Enterprise Value | 4.69B | Income | -27.11M | Sales | 634.21M | Book/sh | 0.88 | Cash/sh | 0.94 |
| Dividend Yield | — | Payout | 0.00% | Employees | 511 | IPO | — | P/E | — | Forward P/E | 17.66 |
| PEG | — | P/S | 7.16 | P/B | 16.39 | P/C | — | EV/EBITDA | 111.78 | EV/Sales | 7.39 |
| Quick Ratio | 1.72 | Current Ratio | 2.84 | Debt/Eq | 161.30 | LT Debt/Eq | — | EPS (ttm) | -0.09 | EPS next Y | 0.82 |
| EPS Growth | -95.50% | Revenue Growth | 23.70% | Earnings | 2026-05-07 | ROA | 2.48% | ROE | -11.58% | ROIC | — |
| Gross Margin | 88.50% | Oper. Margin | 8.61% | Profit Margin | -4.28% | Shs Outstand | 314.00M | Shs Float | 311.44M | Short Float | 6.77% |
| Short Ratio | 5.58 | Short Interest | — | 52W High | 14.48 | 52W Low | 5.51 | Beta | 0.48 | Avg Volume | 4.35M |
| Volume | 2.02M | Target Price | $14.50 | Recom | None | Prev Close | $14.46 | Price | $14.46 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-22 | down | Jefferies | Buy → Hold | $15 |
| 2025-12-29 | down | Leerink Partners | Outperform → Market Perform | $15 |
| 2025-12-22 | down | Citigroup | Buy → Neutral | $15 |
| 2025-12-19 | down | Needham | Buy → Hold | — |
| 2025-12-19 | down | Cantor Fitzgerald | Overweight → Neutral | $15 |
| 2025-12-17 | init | Citigroup | — → Buy | $17 |
| 2025-11-06 | main | JP Morgan | Overweight → Overweight | $19 |
| 2025-11-05 | main | Goldman Sachs | Neutral → Neutral | $11 |
| 2025-09-18 | up | Needham | Hold → Buy | $14 |
| 2025-07-17 | up | Morgan Stanley | Equal-Weight → Overweight | $108 |
| 2025-05-02 | main | UBS | Buy → Buy | $22 |
| 2025-05-02 | main | Goldman Sachs | Neutral → Neutral | $9 |
| 2025-02-20 | main | Wells Fargo | Overweight → Overweight | $17 |
| 2025-02-20 | reit | Needham | Hold → Hold | — |
| 2025-01-15 | reit | Cantor Fitzgerald | Overweight → Overweight | $21 |
| 2025-01-13 | reit | Needham | Hold → Hold | — |
| 2024-12-13 | down | Morgan Stanley | Overweight → Equal-Weight | $12 |
| 2024-11-12 | main | JP Morgan | Overweight → Overweight | $17 |
| 2024-11-07 | main | Guggenheim | Buy → Buy | $15 |
| 2024-11-07 | main | UBS | Buy → Buy | $21 |
- French approval clears way for Amicus (NASDAQ: FOLD) merger with BioMarin - Stock Titan hu, 23 Apr 2026 20
- ServiceNow Before Q1 Earnings: Should You Hold or Fold the Stock? - Zacks Investment Research Mon, 20 Apr 2026 15
- Fold Holdings COO Matt McManus sells $14,925 in company stock By Investing.com - Investing.com Australia Fri, 24 Apr 2026 01
- Amicus Therapeutics (NASDAQ:FOLD) Sets New 12-Month High - Time to Buy? - MarketBeat hu, 23 Apr 2026 17
- How Amicus Therapeutics Inc. (FOLD) Affects Rotational Strategy Timing - Stock Traders Daily ue, 21 Apr 2026 03
- Amicus Gains Final Approval for BioMarin Acquisition Completion - TipRanks hu, 23 Apr 2026 20
- Is Fold Holdings (FLD) stock showing weakness | Fold Holdings Inc. posts 454% negative EPS miss vs forecasts - Financial Update - UBND thành phố Hải Phòng hu, 23 Apr 2026 03
- FOLD Shares Hit 52-Week High: Time to Buy, Sell or Hold the Stock? - Yahoo Finance ue, 16 Dec 2025 08
- FOLD (Amicus Therapeutics Inc.) posts steep Q4 2025 EPS miss, shares edge up slightly in daily trading. - Trending Social Stocks - Cổng thông tin điện tử tỉnh Tây Ninh Wed, 22 Apr 2026 23
- Fold Holdings CFO repass Wolfe sells $354 in common stock - Investing.com Wed, 22 Apr 2026 02
- DraftKings Stock Dips 27% in 3 Months: Should You Hold or Fold? - Zacks Investment Research Fri, 17 Apr 2026 14
- Why is Amicus Therapeutics (FOLD) stock moving (Unchanged) 2026-04-20 - Public Sentiment - Cổng thông tin điện tử tỉnh Lào Cai Mon, 20 Apr 2026 14
- Quanta Trades at a Premium: Should Investors Buy the Stock or Fold? - Yahoo Finance Wed, 08 Apr 2026 07
- Fold Holdings CTO Thomas Dickman sells $91 in company stock after RSU vesting - Investing.com Wed, 22 Apr 2026 01
- Applied Digital Set to Report Q3 Earnings: Hold or Fold the Stock? - Yahoo Finance ue, 07 Apr 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
634.21
+20.05%
|
528.29
+32.29%
|
399.36
+21.30%
|
329.23
|
| Operating Revenue |
|
634.21
+20.05%
|
528.29
+32.29%
|
399.36
+21.30%
|
329.23
|
| Cost Of Revenue |
|
72.93
+37.75%
|
52.94
+41.84%
|
37.33
-3.30%
|
38.60
|
| Reconciled Cost Of Revenue |
|
72.93
+37.75%
|
52.94
+41.84%
|
37.33
-3.30%
|
38.60
|
| Gross Profit |
|
561.28
+18.08%
|
475.35
+31.30%
|
362.03
+24.57%
|
290.63
|
| Operating Expense |
|
526.79
+19.38%
|
441.29
+1.32%
|
435.52
-12.03%
|
495.06
|
| Research And Development |
|
135.84
+24.21%
|
109.36
-28.23%
|
152.38
-44.92%
|
276.68
|
| Selling General And Administration |
|
383.49
+18.59%
|
323.38
+17.48%
|
275.27
+29.21%
|
213.04
|
| Total Expenses |
|
599.72
+21.34%
|
494.23
+4.52%
|
472.85
-11.39%
|
533.66
|
| Operating Income |
|
34.49
+1.25%
|
34.06
+146.35%
|
-73.49
+64.05%
|
-204.43
|
| Total Operating Income As Reported |
|
32.79
+31.81%
|
24.88
+132.22%
|
-77.21
+63.60%
|
-212.12
|
| EBITDA |
|
53.81
+83.10%
|
29.39
+131.92%
|
-92.08
+53.86%
|
-199.58
|
| Normalized EBITDA |
|
55.51
+43.90%
|
38.58
+151.83%
|
-74.43
+61.21%
|
-191.88
|
| Reconciled Depreciation |
|
7.46
-12.72%
|
8.55
+8.56%
|
7.87
+47.38%
|
5.34
|
| EBIT |
|
46.35
+122.39%
|
20.84
+120.85%
|
-99.95
+51.22%
|
-204.92
|
| Total Unusual Items |
|
-1.70
+81.48%
|
-9.19
+47.94%
|
-17.65
-129.40%
|
-7.69
|
| Total Unusual Items Excluding Goodwill |
|
-1.70
+81.48%
|
-9.19
+47.94%
|
-17.65
-129.40%
|
-7.69
|
| Special Income Charges |
|
-1.70
+81.48%
|
-9.19
+47.94%
|
-17.65
-129.40%
|
-7.69
|
| Other Special Charges |
|
—
|
—
|
13.93
|
—
|
| Restructuring And Mergern Acquisition |
|
0.00
-100.00%
|
9.19
+255.71%
|
2.58
+139.61%
|
1.08
|
| Write Off |
|
1.70
|
0.00
-100.00%
|
1.13
-82.86%
|
6.62
|
| Net Income |
|
-27.11
+51.68%
|
-56.11
+62.99%
|
-151.58
+35.92%
|
-236.57
|
| Pretax Income |
|
0.19
+100.66%
|
-28.76
+80.84%
|
-150.10
+37.98%
|
-242.04
|
| Net Non Operating Interest Income Expense |
|
-42.84
+3.05%
|
-44.19
-2.60%
|
-43.07
-26.33%
|
-34.09
|
| Interest Expense Non Operating |
|
46.16
-6.93%
|
49.60
-1.10%
|
50.15
+35.10%
|
37.12
|
| Net Interest Income |
|
-42.84
+3.05%
|
-44.19
-2.60%
|
-43.07
-26.33%
|
-34.09
|
| Interest Expense |
|
46.16
-6.93%
|
49.60
-1.10%
|
50.15
+35.10%
|
37.12
|
| Interest Income Non Operating |
|
3.32
-38.65%
|
5.41
-23.61%
|
7.08
+134.06%
|
3.02
|
| Interest Income |
|
3.32
-38.65%
|
5.41
-23.61%
|
7.08
+134.06%
|
3.02
|
| Other Income Expense |
|
8.54
+145.85%
|
-18.63
+44.45%
|
-33.54
-853.27%
|
-3.52
|
| Other Non Operating Income Expenses |
|
10.24
+208.51%
|
-9.44
+40.57%
|
-15.89
-480.41%
|
4.18
|
| Tax Provision |
|
27.30
-0.18%
|
27.35
+1744.23%
|
1.48
+127.11%
|
-5.47
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+950.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-0.36
+81.48%
|
-1.93
+47.94%
|
-3.71
-2308.70%
|
-0.15
|
| Net Income Including Noncontrolling Interests |
|
-27.11
+51.68%
|
-56.11
+62.99%
|
-151.58
+35.92%
|
-236.57
|
| Net Income From Continuing Operation Net Minority Interest |
|
-27.11
+51.68%
|
-56.11
+62.99%
|
-151.58
+35.92%
|
-236.57
|
| Net Income From Continuing And Discontinued Operation |
|
-27.11
+51.68%
|
-56.11
+62.99%
|
-151.58
+35.92%
|
-236.57
|
| Net Income Continuous Operations |
|
-27.11
+51.68%
|
-56.11
+62.99%
|
-151.58
+35.92%
|
-236.57
|
| Normalized Income |
|
-25.77
+47.25%
|
-48.85
+64.51%
|
-137.64
+39.90%
|
-229.03
|
| Net Income Common Stockholders |
|
-27.11
+51.68%
|
-56.11
+62.99%
|
-151.58
+35.92%
|
-236.57
|
| Diluted EPS |
|
—
|
-0.18
+64.71%
|
-0.51
+37.80%
|
-0.82
|
| Basic EPS |
|
—
|
-0.18
+64.71%
|
-0.51
+37.80%
|
-0.82
|
| Basic Average Shares |
|
—
|
304.38
+3.12%
|
295.16
+2.11%
|
289.06
|
| Diluted Average Shares |
|
—
|
304.38
+3.12%
|
295.16
+2.11%
|
289.06
|
| Diluted NI Availto Com Stockholders |
|
-27.11
+51.68%
|
-56.11
+62.99%
|
-151.58
+35.92%
|
-236.57
|
| Depreciation Amortization Depletion Income Statement |
|
7.46
-12.72%
|
8.55
+8.56%
|
7.87
+47.38%
|
5.34
|
| Depreciation And Amortization In Income Statement |
|
7.46
-12.72%
|
8.55
+8.56%
|
7.87
+47.38%
|
5.34
|
| Line Item | Trend | 2025-12-31 | 2023-12-31 |
|---|---|---|---|
| Total Assets |
|
949.87
+22.11%
|
777.88
|
| Current Assets |
|
676.17
+39.98%
|
483.06
|
| Cash Cash Equivalents And Short Term Investments |
|
293.54
+2.56%
|
286.20
|
| Cash And Cash Equivalents |
|
214.01
-13.35%
|
246.99
|
| Other Short Term Investments |
|
79.53
+102.84%
|
39.21
|
| Receivables |
|
115.31
+31.58%
|
87.63
|
| Accounts Receivable |
|
115.31
+31.58%
|
87.63
|
| Inventory |
|
228.82
+283.31%
|
59.70
|
| Raw Materials |
|
131.17
+333.91%
|
30.23
|
| Work In Process |
|
61.30
+171.29%
|
22.60
|
| Finished Goods |
|
36.34
+429.12%
|
6.87
|
| Prepaid Assets |
|
—
|
—
|
| Other Current Assets |
|
38.51
-22.25%
|
49.53
|
| Total Non Current Assets |
|
273.70
-7.16%
|
294.82
|
| Net PPE |
|
48.25
-16.79%
|
57.98
|
| Accumulated Depreciation |
|
-31.82
-25.14%
|
-25.43
|
| Properties |
|
0.00
|
0.00
|
| Land And Improvements |
|
—
|
—
|
| Machinery Furniture Equipment |
|
10.09
+11.70%
|
9.03
|
| Construction In Progress |
|
0.00
-100.00%
|
3.81
|
| Other Properties |
|
36.91
-13.22%
|
42.53
|
| Leases |
|
33.07
+17.96%
|
28.03
|
| Goodwill And Other Intangible Assets |
|
211.71
-3.01%
|
218.29
|
| Goodwill |
|
197.80
+0.00%
|
197.80
|
| Other Intangible Assets |
|
13.91
-32.09%
|
20.49
|
| Other Non Current Assets |
|
13.74
-25.95%
|
18.55
|
| Total Liabilities Net Minority Interest |
|
675.63
+9.38%
|
617.71
|
| Current Liabilities |
|
237.83
+41.83%
|
167.69
|
| Payables And Accrued Expenses |
|
179.73
+62.37%
|
110.69
|
| Payables |
|
57.44
+108.46%
|
27.55
|
| Accounts Payable |
|
28.63
+89.35%
|
15.12
|
| Other Payable |
|
—
|
—
|
| Current Accrued Expenses |
|
122.29
+47.10%
|
83.14
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
37.68
-1.63%
|
38.30
|
| Total Tax Payable |
|
28.81
+131.70%
|
12.43
|
| Current Debt And Capital Lease Obligation |
|
8.74
+5.01%
|
8.32
|
| Current Capital Lease Obligation |
|
8.74
+5.01%
|
8.32
|
| Other Current Liabilities |
|
11.68
+12.60%
|
10.37
|
| Total Non Current Liabilities Net Minority Interest |
|
437.80
-2.71%
|
450.02
|
| Long Term Debt And Capital Lease Obligation |
|
433.62
-0.71%
|
436.74
|
| Long Term Debt |
|
392.66
+1.24%
|
387.86
|
| Long Term Capital Lease Obligation |
|
40.96
-16.19%
|
48.88
|
| Tradeand Other Payables Non Current |
|
—
|
—
|
| Non Current Deferred Liabilities |
|
—
|
—
|
| Non Current Deferred Taxes Liabilities |
|
—
|
—
|
| Other Non Current Liabilities |
|
4.18
-68.54%
|
13.28
|
| Stockholders Equity |
|
274.24
+71.21%
|
160.17
|
| Common Stock Equity |
|
274.24
+71.21%
|
160.17
|
| Capital Stock |
|
3.04
+4.08%
|
2.92
|
| Common Stock |
|
3.04
+4.08%
|
2.92
|
| Share Issued |
|
310.86
+5.88%
|
293.59
|
| Ordinary Shares Number |
|
310.85
+5.88%
|
293.59
|
| Treasury Shares Number |
|
0.01
|
0.00
|
| Additional Paid In Capital |
|
3,014.46
+6.29%
|
2,836.02
|
| Retained Earnings |
|
-2,767.29
-3.10%
|
-2,684.07
|
| Gains Losses Not Affecting Retained Earnings |
|
24.11
+360.01%
|
5.24
|
| Treasury Stock |
|
0.07
|
—
|
| Total Equity Gross Minority Interest |
|
274.24
+71.21%
|
160.17
|
| Total Capitalization |
|
666.90
+21.69%
|
548.03
|
| Working Capital |
|
438.35
+38.99%
|
315.37
|
| Invested Capital |
|
666.90
+21.69%
|
548.03
|
| Total Debt |
|
442.36
-0.61%
|
445.06
|
| Net Debt |
|
178.65
+26.82%
|
140.86
|
| Capital Lease Obligations |
|
49.70
-13.11%
|
57.20
|
| Net Tangible Assets |
|
62.53
+207.60%
|
-58.11
|
| Tangible Book Value |
|
62.53
+207.60%
|
-58.11
|
| Foreign Currency Translation Adjustments |
|
24.12
+344.28%
|
5.43
|
| Interest Payable |
|
—
|
11.66
|
| Other Equity Interest |
|
—
|
0.07
|
| Unrealized Gain Loss |
|
-0.01
+94.15%
|
-0.19
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
33.15
+197.80%
|
-33.89
+50.95%
|
-69.09
+58.52%
|
-166.57
|
| Cash Flow From Continuing Operating Activities |
|
33.15
+197.80%
|
-33.89
+50.95%
|
-69.09
+58.52%
|
-166.57
|
| Net Income From Continuing Operations |
|
-27.11
+51.68%
|
-56.11
+62.99%
|
-151.58
+35.92%
|
-236.57
|
| Depreciation Amortization Depletion |
|
7.46
-12.72%
|
8.55
+8.56%
|
7.87
+47.38%
|
5.34
|
| Depreciation And Amortization |
|
7.46
-12.72%
|
8.55
+8.56%
|
7.87
+47.38%
|
5.34
|
| Other Non Cash Items |
|
2.57
+13.62%
|
2.26
+114.01%
|
-16.15
-535.02%
|
3.71
|
| Stock Based Compensation |
|
87.41
+2.95%
|
84.91
-1.36%
|
86.08
+12.50%
|
76.51
|
| Asset Impairment Charge |
|
-1.14
-112.36%
|
9.21
+237.73%
|
2.73
-85.00%
|
18.18
|
| Deferred Tax |
|
0.00
|
0.00
+100.00%
|
-4.94
-54977.78%
|
0.01
|
| Deferred Income Tax |
|
0.00
|
0.00
+100.00%
|
-4.94
-54977.78%
|
0.01
|
| Operating Gains Losses |
|
3.59
-77.91%
|
16.23
-51.61%
|
33.55
+448.05%
|
6.12
|
| Net Foreign Currency Exchange Gain Loss |
|
3.59
-77.91%
|
16.23
-17.23%
|
19.61
+220.42%
|
6.12
|
| Change In Working Capital |
|
-39.63
+59.94%
|
-98.94
-271.37%
|
-26.64
+33.19%
|
-39.88
|
| Change In Receivables |
|
-5.86
+69.92%
|
-19.48
+3.10%
|
-20.11
-16.03%
|
-17.33
|
| Changes In Account Receivables |
|
-5.86
+69.92%
|
-19.48
+3.10%
|
-20.11
-16.03%
|
-17.33
|
| Change In Inventory |
|
-111.48
-51.36%
|
-73.65
-65.09%
|
-44.61
-735.00%
|
-5.34
|
| Change In Prepaid Assets |
|
-1.38
-109.90%
|
13.96
+273.17%
|
-8.06
-30.16%
|
-6.19
|
| Change In Payables And Accrued Expense |
|
82.78
+601.07%
|
-16.52
-133.58%
|
49.20
+871.44%
|
-6.38
|
| Change In Payable |
|
82.78
+601.07%
|
-16.52
-133.58%
|
49.20
+871.44%
|
-6.38
|
| Change In Account Payable |
|
82.78
+601.07%
|
-16.52
-133.58%
|
49.20
+871.44%
|
-6.38
|
| Change In Other Working Capital |
|
-3.69
-13.45%
|
-3.25
-6.35%
|
-3.05
+34.12%
|
-4.64
|
| Investing Cash Flow |
|
-46.43
-8191.43%
|
-0.56
-100.57%
|
98.06
+6.23%
|
92.32
|
| Cash Flow From Continuing Investing Activities |
|
-46.43
-8191.43%
|
-0.56
-100.57%
|
98.06
+6.23%
|
92.32
|
| Capital Expenditure |
|
-3.30
+7.23%
|
-3.55
+52.24%
|
-7.44
-97.56%
|
-3.77
|
| Capital Expenditure Reported |
|
-3.30
+7.23%
|
-3.55
+52.24%
|
-7.44
-97.56%
|
-3.77
|
| Net Investment Purchase And Sale |
|
-43.14
-1541.23%
|
2.99
-97.16%
|
105.50
+13.85%
|
92.67
|
| Purchase Of Investment |
|
-94.41
+17.76%
|
-114.79
-25.14%
|
-91.72
+62.29%
|
-243.25
|
| Sale Of Investment |
|
51.27
-56.47%
|
117.78
-40.28%
|
197.23
-41.29%
|
335.93
|
| Net Other Investing Changes |
|
—
|
—
|
—
|
3.41
|
| Financing Cash Flow |
|
0.61
-88.09%
|
5.12
-91.70%
|
61.68
+926.44%
|
-7.46
|
| Cash Flow From Continuing Financing Activities |
|
0.61
-88.09%
|
5.12
-91.70%
|
61.68
+926.44%
|
-7.46
|
| Net Issuance Payments Of Debt |
|
-0.27
-180.41%
|
-0.10
+99.54%
|
-20.96
-7305.65%
|
-0.28
|
| Issuance Of Debt |
|
0.00
|
0.00
-100.00%
|
387.36
|
0.00
|
| Repayment Of Debt |
|
-0.27
-180.41%
|
-0.10
+99.98%
|
-408.32
-144181.98%
|
-0.28
|
| Long Term Debt Issuance |
|
0.00
|
0.00
-100.00%
|
387.36
|
0.00
|
| Long Term Debt Payments |
|
-0.27
-180.41%
|
-0.10
+99.98%
|
-408.32
-144181.98%
|
-0.28
|
| Net Long Term Debt Issuance |
|
-0.27
-180.41%
|
-0.10
+99.54%
|
-20.96
-7305.65%
|
-0.28
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
19.57
-78.95%
|
92.94
|
0.00
|
| Proceeds From Stock Option Exercised |
|
19.20
+150.16%
|
7.68
-25.27%
|
10.27
+138.35%
|
4.31
|
| Net Other Financing Charges |
|
-18.32
+16.81%
|
-22.02
-7.06%
|
-20.57
-79.05%
|
-11.49
|
| Changes In Cash |
|
-12.68
+56.78%
|
-29.33
-132.36%
|
90.65
+210.92%
|
-81.72
|
| Effect Of Exchange Rate Changes |
|
13.28
+429.37%
|
-4.03
-163.86%
|
6.31
+143.18%
|
-14.62
|
| Beginning Cash Position |
|
216.72
-13.34%
|
250.08
+63.33%
|
153.12
-38.62%
|
249.46
|
| End Cash Position |
|
217.32
+0.28%
|
216.72
-13.34%
|
250.08
+63.33%
|
153.12
|
| Free Cash Flow |
|
29.85
+179.72%
|
-37.44
+51.07%
|
-76.53
+55.07%
|
-170.34
|
| Interest Paid Supplemental Data |
|
43.61
-26.04%
|
58.96
+63.37%
|
36.09
+5.04%
|
34.36
|
| Income Tax Paid Supplemental Data |
|
14.89
+81.32%
|
8.21
-3.65%
|
8.53
+697.47%
|
1.07
|
| Common Stock Issuance |
|
0.00
-100.00%
|
19.57
-78.95%
|
92.94
|
0.00
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
19.57
-78.95%
|
92.94
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-23 View
- 42026-03-04 View
- 8-K2026-03-03 View
- 10-K2026-02-20 View
- 8-K2026-02-20 View
- 8-K2026-01-26 View
- 42026-01-22 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42025-12-30 View
- 42025-12-30 View
- 42025-12-23 View
- 8-K2025-12-19 View
- 42025-12-17 View
- 42025-12-17 View
- 42025-12-03 View
- 42025-12-03 View
- 42025-11-26 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|